Clinical Trial · NCT01873248

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

Overview

Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Early Phase 1

Contacts

Johannes Czernin, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01873248

Drug / Compound

DOTATATE

Isotope(s):

Target(s):

SSTR2

Ligand Class: Peptides

Chelator: DOTA

Eligibility

Inclusion

Known diagnosis of NET, suspected SSTR positive tumors or suspected NET recurrence.
Females of childbearing potential must have a negative pregnancy test at screening/baseline.

Exclusion

Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments.
Inability to lie still for the entire imaging time.
Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT and MRI that will result.
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
Recognized concurrent active infection.

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…